In 2017 the therapeutic adjuvant landscape of HER2-positive eBC was enriched by the approval of pertuzumab, a monoclonal antibody against HER2 that prevents HER2/HER3 dimerization inhibiting cell survival and proliferation signaling, in combination with trastuzumab for 1 year and chemotherapy for high-risk patients (node-positive or tumor diameter greater than 1 cm), based on the primary analysis of the APHINITY trial [67]. Here, ERBB2 is linked to neoplasm.